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Abstract
Sensitive monitoring should be used when prescribing intravenous fluids for volume resuscitation. The extent and
duration of tissue hypoperfusion determine the severity of cellular damage, which should be kept to a minimum
with timely volume substitution. Optimizing the filling status to normovolaemia may boost the resuscitation
success. Macrocirculatory pressure values are not sensitive in this indication. While the Surviving Sepsis Campaign
guidelines focus on these conventional pressure parameters, the guidelines from the European Society of
Anaesthesiology (ESA) on perioperative bleeding management recommend individualized care by monitoring the
actual volume status and correcting hypovolaemia promptly if present. The motto is: ‘give what is missing’. The
credo of the ESA guidelines is to use management algorithms with predefined intervention triggers. Stop signals
should help in avoiding hyper-resuscitation. The high-quality evidence-based S3 guidelines on volume therapy in
adults have recently been prepared by 14 German scientific societies. Statements include, for example, repeated
clinical inspection including turgor of the skin and mucosa. Adjunctive laboratory parameters such as central
venous oxygen saturation, lactate, base excess and haematocrit should be considered. The S3 guidelines propose
the use of flow-based and/or dynamic preload parameters for guiding volume therapy. Fluid challenges and/or the
leg-raising test (autotransfusion) should be performed. The statement from the Co-ordination group for Mutual
Recognition and Decentralized Procedures–Human informs healthcare professionals to consider applying
individualized medicine and using sensitive monitoring to assess hypovolaemia. The authorities encourage a
personalized goal-directed volume resuscitation technique.
Introduction
Organ function is dependent upon substrate flow into the
tissue and outflow of waste products. Organ perfusion is
generated by pressure gradients on the hydrostatic col-
umn in the vascular compartments of macrocirculation
and microcirculation. Accordingly, several factors are
essential for maintaining adequate tissue perfusion: pres-
sures, filling status, vascular compartment diameter, and
capillary density and permeability. This short review
summarizes the rationale of the answer given in the
respective presentation at the Meeting on the Future of
Critical Care Medicine (FCCM) in Längenfeld, Austria,
to the question of whether or not we should monitor
parameters beyond macrocirculatory pressure values.
Considering volume management, the answer is ‘yes’: we
should indeed include flow-based monitoring (cardiac
output) and/or dynamic preload parameters (such as
stroke volume variation, pulse pressure variation) into
our volume resuscitation protocols. In terms of clinicians’
behaviour, the answer may sometimes be ‘no’; because if
we all always swim with the mainstream flow, progress
and innovation would be impossible.
Dissociation between macrocirculation and
microcirculation
Blood pressure in the macrocirculation can be measured
in clinical practice by non-invasive or invasive monitor-
ing in the arterial or central venous compartments. Con-
ventional blood pressure monitoring is well accepted
among clinicians and patients, is widespread and is used
worldwide. Despite the intriguing simplicity of this con-
ventional pressure monitoring technique, it cannot
assess hydrostatic and oncotic pressures at the microcir-
culatory level. Monitoring mean arterial pressure and
central venous pressure (CVP) alone are misleading if
convection and diffusion at the microcirculatory level, as
well as flow, filling status and vessel capacity, are not
considered. Theoretically, pressure values at the macro-
circulatory and microcirculatory level do not necessarily
change in parallel upon pharmacological intervention:
for example, vasoconstrictors increase afterload and
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mean arterial blood pressure to acceptable values in the
macrocirculation but may shut down downstream perfu-
sion in the microcirculation, thus aggravating organ dys-
function. In this scenario, perfusion will get even worse
in the presence of hypovolaemia and hypoviscosity. On
the other hand, vasodilators decrease afterload and
mean arterial pressures but may recruit capillaries and
decrease diffusion distances at the microcirculatory
level, thus supporting tissue perfusion and organ func-
tion. In this scenario, monitoring and optimizing the fill-
ing status to normovolaemia may boost the resuscitation
success.
Techniques for microcirculatory-targeted resuscitation
are on the horizon (e.g. orthogonal polarized spectral and
sidestream darkfield imaging techniques, near-infrared
spectroscopy, pCO2, contrast-enhanced ultrasonography
and microdialysis). Current algorithms even incorporat-
ing microcirculatory parameters failed to improve short-
term patient outcome [1]. It appears rational and highly
worthwhile to proceed with clinical studies in this field.
What do the guidelines recommend?
Surviving Sepsis Campaign
The Surviving Sepsis Campaign [2] is increasingly criti-
cized because of its focus on conventional management
criteria: CVP 8-12 mmHg, mean arterial blood pressure
>65 mmHg, urine >0.5 ml/kg/hour, central venous oxy-
gen saturation (ScvO2) >70%, lactate <1.5 mmol/l and
haemoglobin level >10 g/dl.
CVP remains the most widely used clinical marker of
volume status, despite numerous studies showing no asso-
ciation between CVP and circulating blood volume [3].
Guidelines from the European Society of Anaesthesiology
The European Society of Anaesthesiology (ESA) published
guidelines on the management of severe bleeding [4].
Severe blood loss leads to absolute hypovolaemia which
requires volume resuscitation. Therefore, one chapter in
the ESA guidelines is dedicated to the topic of infusion
therapy. One key message of the ESA guidelines is to deli-
ver individualized care by monitoring the actual status and
correcting coagulopathic deficits and/or hypovolaemia
promptly if present. The motto is: ‘give what is missing’.
The credo of the ESA guidelines is to use management
algorithms with predefined intervention triggers according
to another motto: ‘use a protocol’. A hospital-internal
draft of a management protocol is shown in Figure 1.
Some examples of respective recommendations are as
follows:
• We recommend aggressive and timely stabilization
of cardiac preload throughout the surgical procedure, as
this appears beneficial to the patient. Grade 1B
Hypovolaemia in bleeding decreases cardiac output
and tissue oxygen supply. Both the extent and duration
of tissue hypoperfusion determine the severity of cellular
damage, which should be kept to a minimum with
timely volume substitution. The most extensively stu-
died and successfully used method to maximize cardiac
Figure 1 Draft monitoring protocol for volume resuscitation at the Evangelical Hospital Vienna. ABG arterial blood gas analysis, asap as
soon as possible, CVP central venous pressure, GDT goal-directed therapy, HR heart rate, IAP intraabdominal pressure, MAP mean arterial blood
pressure, PLR passive leg-raising test, RBC red blood cell concentrate, ScvO2 central venous oxygen saturation, SVV stroke volume variation.
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preload is the oesophageal Doppler device [5-7]. Sono-
graphic evaluation of intravascular volume status (e.g.
inferior vena cava collapsibility index) is increasingly
applied at the point of care [8]. Several studies have
demonstrated that dynamic parameters such as stroke
volume variation or pulse pressure variation provide
prediction of fluid responsiveness in mechanically venti-
lated patients with normal heart rhythm. Fluid chal-
lenges and the leg-raising test represent simple and
valid alternatives [9]. Two recent meta-analyses con-
cluded that a goal-directed approach to maintaining tis-
sue perfusion reduces mortality, postoperative organ
failure and surgical complications in high-risk surgical
patients [10,11]. The ESA guidelines further recommend
repeated monitoring of tissue perfusion, tissue oxygena-
tion and the dynamics of blood loss during acute bleed-
ing. Lactate clearance and base excess have been
proposed as metabolic parameters for indirectly asses-
sing tissue perfusion.
• We recommend against the use of central venous
pressure and pulmonary artery occlusion pressure as the
only variables to guide fluid therapy and optimize pre-
load during severe bleeding; dynamic assessment of fluid
responsiveness and non-invasive measurement of cardiac
output should be considered instead. Grade 1B
This recommendation clearly describes the inferiority
of sole pressure-oriented monitoring. To determine the
amount of fluid required, modern monitoring techni-
ques are necessary. The monitored variable should pre-
dict whether or not a fluid bolus will raise cardiac
output.
• We recommend the avoidance of hypervolaemia
with crystalloids or colloids to a level exceeding the
interstitial space in steady state, and beyond an optimal
cardiac preload. Grade 1B
The motto is: ‘keep the bleeding patient neither too wet
nor too dry’. The relationship between risks and total
volume infused appears to follow a U-shaped curve:
infusing too much can be as deleterious as infusing too
little [12]. Fluid excess can have a negative impact not
only on dilutional coagulopathy [13], but also on cardiac,
pulmonary and bowel function, wound healing as well as
water and sodium regulation [14]. Iatrogenic hypervolae-
mia predisposes patients to interstitial oedema, which
appears to be associated with perioperative mortality
[15]. It requires sensitive monitoring for the filling status
in order to identify the ‘stop signal’ for further infusion
therapy. An increase in CVP could be used as a stop
signal.
In the ESA guidelines, monitoring technologies and their
limitations are not described, monitoring-dependent inter-
vention cutoff points are not reported and differential indi-
cations for monitoring modalities in specific clinical
situations are not suggested. Clinicians have to select the
most appropriate monitoring technique; for example,
using the internal jugular or femoral vein collapsibility
index during fluid resuscitation in patients with elevated
intra-abdominal pressure or morbid obesity where sono-
graphic acquisition of the inferior vena cava collapsibility
index is not feasible [8].
German S3 guidelines on volume therapy in adults
Recently the high-quality evidence-based S3 guidelines
on volume therapy in adults have been published [16].
The German Society of Anaesthesiology and Intensive
Care Medicine (DGAI) masterminded this interdisciplin-
ary project in collaboration with 13 German scientific
societies. Together, these guidelines represent the con-
sensus among general and visceral surgeons, gynaecolo-
gists and obstetricians, urologists, internal medicine
physicians and cardiologists, intensive care, neurointen-
sive care and emergency physicians, orthopaedic and
trauma surgeons, cardiothoracic and vascular surgeons,
as well as nurse scientists. Eventual dissent is clearly
marked in the guidelines. The S3 guidelines are cur-
rently only available in German but the translation into
English is ongoing.
Statements are in line with the ESA guidelines [4].
Patient’s history assessment and repeated clinical inspec-
tion of the actual volume status are recommended (e.g. by
assessing turgor of the skin, mucosa) (grade of recommen-
dation (GoR): A). Adjunctive laboratory parameters such
as ScvO2, lactate, base excess and haematocrit should be
considered (GoR: A). CVP is inadequate for detecting
volume deficits in perioperative and critically ill patients
(GoR: A). The German Sepsis Society disagreed with this
recommendation and with a number of further recom-
mendations which are not in line with the Surviving Sepsis
Campaign [2]. The S3 guidelines propose the use of flow-
based and/or dynamic preload parameters for guiding
volume therapy. In high-risk patients–for example, older
patients with hip-near fracture, major abdominal surgery
or cardiovascular comorbidities compromising the capabil-
ity for haemodynamic compensation–volume monitoring
should be performed throughout major procedures (GoR:
0). Implementation of flow-based parameters into prede-
fined management algorithms is recommended (GoR: B).
Fluid challenges and/or the leg-raising test (autotransfu-
sion) should be performed (GoR: B). If possible, volume
status and responsiveness to the fluid challenge should be
assessed by cardiac output monitoring or dynamic preload
monitoring (GoR: B). Only initial fluid responsiveness
could be roughly appreciated by changes in mean arterial
pressure (GoR: 0). In intensive care patients, the S3 guide-
lines suggest monitoring means of intrathoracic blood
volume, Doppler, B-mode and/or transthoracic echocar-
diography (GoR: 0). In haemodynamic instability (of sus-
pected cardiac origin), monitoring using echocardiography
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is suggested (GoR: A). Echocardiography is also suggested
for detecting interstitial oedema and extravasation (e.g. in
the pleura, abdomen, intestine). These signs should be
used as stop signals for further volume therapy.
Focus on inadequate monitoring parameters results in
misleading interpretations of therapeutic interventions,
and even recent randomized controlled trials used con-
ventional static pressure-based indices as measures for
haemodynamic stabilization [17,18]. The authors of the
S3 guidelines therefore propose that future studies on
volume management must employ adequate parameters
for detecting hypovolaemia, must prove targeted correc-
tion according to a management algorithm, and must
avoid overdosing.
Societal perspective
After the statement from the European Medicines
Agency (EMA) [19], hydroxyethyl starch (HES) is less
prescribed Europe-wide because of medico-legal consid-
erations. The EMA supported us to think twice before
infusing any fluid intravenously and to acknowledge that
fluids are drugs. Interestingly, other colloids are also
increasingly being avoided although the evidence for
safety problems for albumin or gelatin is scarce. In the
statement from the Co-ordination Group for Mutual
Recognition and Decentralized Procedures–Human
(CMDh), healthcare professionals are informed to con-
sider that ‘HES solutions should only be used for the
treatment of hypovolaemia due to blood loss when crys-
talloids alone are not considered sufficient’ [19].
With this article the authorities reinforce applying indi-
vidualized medicine and using, for example, preload
monitoring to assess hypovolaemia. This is a step forward
from conventional pressure-based management strate-
gies. Interestingly, blood loss is defined as a prerequisite
for colloidal HES infusion; replacement of extracellular
water losses is clearly not listed as an indication for a col-
loidal infusion. The wording in this article leaves room
for individual decision-making because the lack of effi-
cacy of crystalloids does not need to be proven in the
individual patient before choosing a more potent colloid,
but only anticipated by the attending clinician.
’HES solutions should be used at the lowest effective
dose for the shortest period of time. Treatment
should be guided by continuous haemodynamic
monitoring so that the infusion is stopped as soon
as appropriate haemodynamic goals have been
achieved [19].’
The CMDh group requires clinicians to monitor the hae-
modynamic status continuously, however, without defining
the appropriate methodology. From a practical viewpoint,
and extrapolated from the ESA and S3 guidelines [4,16],
appropriate haemodynamic monitoring will most probably
not be restricted to conventional pressure-oriented moni-
toring but will comprise volumetric preload testing. The
CMDh statement reminds us about a general principle in
pharmacotherapy: repeatedly reconsider the indication and
avoid overdosing. The therapeutic target is to achieve nor-
movolaemia, not infusing beyond. The CMDh statement
also suggests the use of protocols with predefined triggers
for infusion and as stop signals for further infusion.
Thereby, the authorities encourage a personalized low-HES
volume resuscitation technique. Contraindications against
the use of HES, such as in sepsis and burn, are clearly listed
in the EMA resolution [19].
Goal-directed therapy
The term goal-directed therapy (GDT) in the context of
volume therapy means rational, comprehensible, stan-
dardized and individualized indication and dosing of
infusions. The alternative treatment option is adminis-
tration of infusions at the clinicians’ discretion, based on
experience, intuition and gut feeling. By recommending
the use of algorithms with predefined intervention trig-
gers, S3 and ESA guidelines as well as the EMA propose
GDT for volume management over non-protocolized
care [4,16,19]. Since GDT has repeatedly been con-
firmed to reduce the length of hospital stay and post-
operative complication rates, which per se determine
long-term survival after major surgery [20], national
authorities such as the National Institute for Clinical
Excellence (NICE) in the UK facilitate top-down GDT
implementation with accounting incentives.
The term GDT is not restricted to protocols incorpor-
ating flow-based parameters for guiding volume indica-
tion and dosing, but is also used for protocols with
conventional macrocirculatory pressure-based para-
meters or microcirculatory parameters. However, using
predominantly volume status-insensitive pressure para-
meters, clinical outcome was not improved in GDT-
treated groups [21,22]. Obviously, determining the mean
arterial pressure, CVP and ScvO2 does not increase sur-
vival. The number of trials investigating flow-based
GDT is steadily increasing. First-generation algorithms
aimed at maximizing stroke volume before the hit of
surgery and bleeding [23]. This approach resulted in
high-volume loading which often was not required dur-
ing an uneventful course of surgery. Second-generation
algorithms aimed for optimizing stroke volume only
when found low in the presence of clinical signs of
hypoperfusion, including stop signals preventing volume
overload, and incorporating also protocol pathways to a
rational use of vasoactive drugs [24,25]. The ideal GDT
has not yet been defined–we are climbing up the learn-
ing curve. Future algorithms may personalize the GDT
concept further by selecting the most appropriate
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monitoring technology for specific clinical scenarios; for
example, in patients with active breathing efforts, with
reduced left ventricular ejection fraction or with intrao-
perative changes in body positioning.
The ideal endpoint for clinical studies on GDT has
not yet been defined either–mortality may not be ade-
quate for the supportive therapy of volume resuscitation.
In perioperative patients mortality is low, and in sepsis
and critical illness mortality is affected by various patho-
mechanisms and interventions other than tissue perfu-
sion and recruitment of weak microcirculatory units. It
is conceivable that, despite optimized tissue perfusion,
cytopathic hypoxia leads to cellular death, organ dys-
function and clinical death because failing mitochondria
cannot extract delivered oxygen [26]. Intervening only
on the small wheel of volume therapy in the complex
sepsis syndrome cannot easily lead to success.
A direct efficacy endpoint in GDT studies could be
the prevention of fluid overload. Studies have shown
that a positive fluid balance is associated with increased
mortality [27]. Stroke volume-directed GDT demon-
strated volume efficacy of HES in neurosurgical patients:
the amount of crystalloid needed in the prone position
was 25% higher compared with HES [28].
National quality improvement programmes [20,29]
may help us identify successful healthcare practices in
real clinical life. If flow-based goal-directed volume
resuscitation is adding a sustained net-clinical benefit, a
signal should emerge in an outcome-oriented database.
Obviously, the quality of benchmarking is dependent
upon careful selection of meaningful outcome quality
indicators, avoidance of missing data by automated doc-
umentation without excess workload to healthcare pro-
viders, and–most important–careful interpretation of
gathered results.
Conclusion
We should critically review a pressure-guided standard
resuscitation strategy based on the Surviving Sepsis
Guidelines. New evidence-based international and inter-
disciplinary guidelines and the EMA support the concept
and advice to implement flow and preload parameters
into our volume resuscitation protocols. Yes, we should
go with flow-based monitoring (cardiac output) and/or
dynamic preload parameters (such as stroke volume var-
iation, pulse pressure variation) rather than only with
pressure-based parameters (such as mean arterial blood
pressure, CVP). Clinicians are encouraged to compile
flow-based GDT and further studies are highly warranted
for improving the future in critical care medicine.
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